These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 25597601)

  • 1. Association between adipokine and myeloperoxidase levels in patients with coronary artery disease.
    Basati G; Emami Razavi A; Abdi S; Sarrafzadegan N
    Acta Med Iran; 2015; 53(1):25-9. PubMed ID: 25597601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High plasma levels of adipocytokines are associated with platelet activation in patients with coronary artery disease.
    Bigalke B; Stellos K; Geisler T; Seizer P; Mozes V; Gawaz M
    Platelets; 2010; 21(1):11-9. PubMed ID: 19954410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of adiponectin and leptin to coronary artery disease, classical cardiovascular risk factors and atherothrombotic biomarkers in the IARS cohort.
    Shanker J; Rao VS; Ravindran V; Dhanalakshmi B; Hebbagodi S; Kakkar VV
    Thromb Haemost; 2012 Oct; 108(4):769-80. PubMed ID: 22955445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between myeloperoxidase levels and risk of coronary artery disease.
    Zhang R; Brennan ML; Fu X; Aviles RJ; Pearce GL; Penn MS; Topol EJ; Sprecher DL; Hazen SL
    JAMA; 2001 Nov; 286(17):2136-42. PubMed ID: 11694155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes.
    Ndrepepa G; Braun S; Mehilli J; von Beckerath N; Schömig A; Kastrati A
    Eur J Clin Invest; 2008 Feb; 38(2):90-6. PubMed ID: 18226042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of Plasma Myeloperoxidase Level with Risk of Coronary Artery Disease in Patients with Type 2 Diabetes.
    Song P; Xu J; Song Y; Jiang S; Yuan H; Zhang X
    Dis Markers; 2015; 2015():761939. PubMed ID: 26451069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gender-specific correlation between plasma myeloperoxidase levels and serum high-density lipoprotein-associated paraoxonase-1 levels in patients with stable and unstable coronary artery disease.
    Yunoki K; Naruko T; Inaba M; Inoue T; Nakagawa M; Sugioka K; Ohsawa M; Iwasa Y; Komatsu R; Itoh A; Haze K; Yoshiyama M; Becker AE; Ueda M
    Atherosclerosis; 2013 Dec; 231(2):308-14. PubMed ID: 24267244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated plasma myeloperoxidase levels in relation to circulating inflammatory markers in coronary artery disease.
    Samsamshariat SZ; Basati G; Movahedian A; Pourfarzam M; Sarrafzadegan N
    Biomark Med; 2011 Jun; 5(3):377-85. PubMed ID: 21657847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between myeloperoxidase polymorphisms and its plasma levels with severity of coronary artery disease.
    Wainstein RV; Wainstein MV; Ribeiro JP; Dornelles LV; Tozzati P; Ashton-Prolla P; Ewald IP; Vietta G; Polanczyk CA
    Clin Biochem; 2010 Jan; 43(1-2):57-62. PubMed ID: 19651119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low serum level of secreted frizzled-related protein 5, an anti-inflammatory adipokine, is associated with coronary artery disease.
    Miyoshi T; Doi M; Usui S; Iwamoto M; Kajiya M; Takeda K; Nosaka K; Nakayama R; Okawa K; Takagi W; Nakamura K; Hirohata S; Ito H
    Atherosclerosis; 2014 Apr; 233(2):454-459. PubMed ID: 24530778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study.
    Meuwese MC; Stroes ES; Hazen SL; van Miert JN; Kuivenhoven JA; Schaub RG; Wareham NJ; Luben R; Kastelein JJ; Khaw KT; Boekholdt SM
    J Am Coll Cardiol; 2007 Jul; 50(2):159-65. PubMed ID: 17616301
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The combined utility of myeloperoxidase (MPO) and paraoxonase 1 (PON1) as two important HDL-associated enzymes in coronary artery disease: Which has a stronger predictive role?
    Variji A; Shokri Y; Fallahpour S; Zargari M; Bagheri B; Abediankenari S; Alizadeh A; Mahrooz A
    Atherosclerosis; 2019 Jan; 280():7-13. PubMed ID: 30448568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease.
    Stefanescu A; Braun S; Ndrepepa G; Koppara T; Pavaci H; Mehilli J; Schömig A; Kastrati A
    Am Heart J; 2008 Feb; 155(2):356-60. PubMed ID: 18215608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myeloperoxidase level and inflammatory markers and lipid and lipoprotein parameters in stable coronary artery disease.
    Kimak E; Zięba B; Duma D; Solski J
    Lipids Health Dis; 2018 Apr; 17(1):71. PubMed ID: 29618370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adipokines and severity and progression of coronary artery calcium: Findings from the Rancho Bernardo Study.
    Larsen BA; Laughlin GA; Cummins K; Barrett-Connor E; Wassel CL
    Atherosclerosis; 2017 Oct; 265():1-6. PubMed ID: 28825974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development, optimization and validation of an absolute specific assay for active myeloperoxidase (MPO) and its application in a clinical context: role of MPO specific activity in coronary artery disease.
    Trentini A; Rosta V; Spadaro S; Bellini T; Rizzo P; Vieceli Dalla Sega F; Passaro A; Zuliani G; Gentili V; Campo G; Cervellati C
    Clin Chem Lab Med; 2020 Sep; 58(10):1749-1758. PubMed ID: 32031967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Active and total myeloperoxidase in coronary artery disease and relation to clinical instability.
    Gach O; Brogneaux C; Franck T; Serteyn D; Legrand V; Pierard LA; Magne J
    Acta Cardiol; 2015 Oct; 70(5):522-7. PubMed ID: 26567811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome.
    Cavusoglu E; Ruwende C; Eng C; Chopra V; Yanamadala S; Clark LT; Pinsky DJ; Marmur JD
    Am J Cardiol; 2007 May; 99(10):1364-8. PubMed ID: 17493461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma myeloperoxidase is related to the severity of coronary artery disease.
    Düzgünçinar O; Yavuz B; Hazirolan T; Deniz A; Tokgözoğlu SL; Akata D; Demirpençe E
    Acta Cardiol; 2008 Apr; 63(2):147-52. PubMed ID: 18468192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective, randomized, single-blind comparison of effects of 6 months of treatment with telmisartan versus enalapril on high-molecular-weight adiponectin concentrations in patients with coronary artery disease.
    Satoh M; Tabuchi T; Minami Y; Takahashi Y; Itoh T; Nakamura M
    Clin Ther; 2009 Oct; 31(10):2113-25. PubMed ID: 19922882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.